Good morning,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
One of the most frustrating things for an investor in early-stage biotech companies is opening the 4C report every quarter and seeing the cash balance drop more than expected.
… particularly if the company hasn’t announced anything material.
Where does the money go?
Well, today I’m going to try to answer that question.
I was first introduced to James Cooney and Nenad Sejic from Pipeline Bio a few months back.
Pipeline Bio is like a marketplace or directory for biotech service providers.
The company that writes the grant funding.
The CRO that provides clinical trial work.
The vendor who grows lab rats.
Anything you can think of to service the biotech industry, all in one place.
Anyways, I like the product and the guys behind it, so I asked them if they would be interested in putting together a guest post for the Armchair Army covering a topic that’s been gnawing at me since I started investing in biotechs.
Where does the money go?
But first…
The Pulse Check
Anteris Technologies (ASX: AVR) announces the treatment of the first U.S. patients in the PARADIGM Trial, a pivotal study for its Transcatheter Heart Valve. (AVR)
🪑There was a good write-up on Anteris in Forbes this week as well: The Australian medtech rebuilding the aortic valve from scratch
TruScreen (ASX: TRU) partners with LASUTH on a US$300,000 Gates Foundation grant application to validate its cervical cancer screening device in Nigeria. (TRU)
🪑 If every company announced the grants that they applied for (not just the ones that they got) the ASX Market Announcement Platform would collapse.
Maybe just make the announcement WHEN you get the grant next time.
Argent BioPharma (ASX: RGT) appoints Andrew Chapman as Executive Director. (RGT)
Noxopharm (ASX: NOX) has engaged Novotech, a CRO, to prepare for a pre-IND meeting with the US FDA for its topical gel for lupus.
🪑Milsteone ticked.
Rhythm Biosciences (ASX: RHY) publishes early case studies on real-world applications of its blood-based colorectal cancer triage test. (RHY)
🪑When I read the announcement highlights, I rolled my eyes… what does “early clinical adoption” even mean?
BUT, after reading through the whole announcement, I found the case studies really helpful for understanding the ‘type’ of patient for whom RHY’s product would be relevant.
Still, it’s hard to extrapolate these case studies into numbers and revenues, but I liked the context and was happy that my initial instinct on the announcement was wrong.
Algorae Pharmaceuticals (ASX: 1AI) has signed a Licence & Supply Agreement with Torrent Pharmaceuticals to commercialise two generic prescription molecules in Australia and New Zealand. (1AI)
🪑 Bit by bit, the generics strategy is coming together.
Under the Microscope
Hi Armchair Army,
James Cooney and Nenad Sejic here.
We spent many years working in the Australian life sciences sector in research and industry roles before teaming up to build Pipeline Bio.
Pipeline Bio is an online platform that centralises the way biotech and research teams find and engage with Australian scientific service providers.
The Armchair Analyst asked us to comment on some of the hidden costs in biotech R&D and their implications for investors.
It’s something we’ve seen firsthand, and the reason we’re building Pipeline Bio.
One of the biggest questions for investors in ASX-listed biotech companies is where does the money go?
All we see is the “Research & Development” line item in the quarterly 4C report.
But what does that actually mean? Why have costs gone up so much?
Finally, what are the questions that you, as an investor, can ask companies to make sure that your capital is being reasonably spent on R&D?
Let’s set the scene.
In 2023, the ATO published its R&D Tax Incentive Transparency Report, recording approximately $2.8 billion in R&D expenditure across 1,000 Australian healthcare and life sciences organisations.
With the top 50 spenders accounting for nearly half of that.
So where does this money actually go?
Who Actually Gets Paid
Most biotech companies, particularly at the ASX small-cap end, do not run experiments in-house.
They operate as relatively small core teams directing a network of external providers to advance their programs.
Like an orchestra.
Outsourcing R&D to service providers is not a bug; it's a feature of an industry where capabilities are too specialised and capital-intensive for any single company to maintain in-house.
A typical development program is therefore distributed across a set of specialised service providers, each responsible for a distinct part of the process:
CROs (Contract Research Organisations): design and run preclinical studies and clinical trials. They translate a scientific concept into the evidence base required for regulatory approval. A single program often engages multiple CROs across several stages of development.
CDMOs (Contract Development and Manufacturing Organisations): develop the manufacturing process and produce the actual drug material. This work is capital-intensive and highly regulated, spanning everything from early formulation through to clinical supply.
Specialist labs: Perform bioanalytical testing and assays measuring drug levels, safety markers, or biological responses that CROs and CDMOs do not handle in-house.
Regulatory consultants: Guide the company’s interactions with the TGA and FDA: advising on trial design, preparing submissions, and navigating agency requirements.
Academic facilities: Provide access to specialised equipment, techniques, or expertise that sits outside the commercial provider network.
Each plays a distinct role, and none are interchangeable.
Importantly, each engagement is sourced, negotiated, and managed separately, independently of what every other provider is doing.
The biotech company sits at the centre of all of it all.
Coordinating across providers who share no common systems and have no visibility into each other's work.
That coordination is a substantial operational undertaking with real financial consequences.
(and why things can get expensive for early-stage biotech companies)
Why Costs Escalate?
The cost of biotech R&D is high for structural reasons, not incidental, and they compound across the development lifecycle.
The most fundamental driver is failure.
Industry-wide clinical success rates are between 5% and 10%, meaning companies must fund all programs that don't work, not just those that do.
(No refunds if the placebo works better than your drug)
On top of that, clinical trials, manufacturing, and regulatory compliance are substantial costs in their own right.
Phase III studies alone can run into the hundreds of millions, and the costs of GMP manufacturing and regulatory documentation accumulate across the entire development timeline regardless of whether the science ultimately succeeds.
Less well recognised is the coordination overhead that comes with operating across a distributed network of service providers.
Sourcing, engaging, and managing external providers is itself a time-intensive and often inefficient process, and the friction it creates has real financial consequences.
While not the largest driver of biotech spend, it is among the most addressable.
All of this operates in the background, and investors just get the call-up for the next capital raise.
In the Australian context, there is an additional policy layer that shapes how these costs are experienced, and that carries its own second-order effects.
The Role of the R&D Tax Incentive in Cost Behaviour
In Australia, these dynamics are further shaped by the R&D Tax Incentive (RDTI), which changes how costs are experienced.
The RDTI provides eligible companies with a refundable tax offset (up to 43.5%) on qualifying research and development expenditure.
It is a genuine structural advantage for biotech companies, extending their runway and supporting early-stage development, making Australia a comparatively attractive location for R&D.
It is deeply embedded in how the industry operates.
Companies plan their budgets assuming the refund, structure their activities to maximise eligible spend, and investors and lenders factor it into funding decisions and capital planning.
A whole industry of debt financing secured against the R&D tax incentive emerged…
(But that’s a story for another time)
Overall, the R&D tax incentive is a net benefit for Australian innovation, serving as the largest government lever to encourage private-sector R&D and boost national competitiveness.
But it also has second-order effects that investors should understand.
First, it reduces price sensitivity.
When a portion of spend is rebated, the effective cost of services falls, allowing providers to sustain pricing that might not hold in unsubsidised markets.
Second, it can encourage activity over discipline.
Programs that might not clear a strict capital allocation review become easier to justify.
RDTI claims are not always a signal of high-quality R&D deployment; they can reflect activity that would have been marginal without the subsidy.
Third, R&D financing can bring forward cash, masking underlying burn and making execution inefficiencies less visible in the short term.
Fourth, grant overlap introduces clawback risk.
Where RDTI claims intersect with grant-funded activity, the net benefit can be reduced or reversed, particularly where risk is not fully borne by the company.
For investors, this creates uncertainty around the durability of claimed benefits and warrants scrutiny of any disclosed overlap.
The clawback rule is under review (Strategic Examination of R&D report), and changes here could materially shift outcomes.
Finally, classification can distort perception, with RDTI receipts occasionally presented in ways that make pre-revenue companies appear more advanced commercially.
For investors reading ASX financials, it is worth confirming how RDTI receipts are categorised.
The result is a system that supports spending, but can also obscure how efficiently that capital is deployed.
Where Capital Leaks
Beyond the direct costs of engaging external providers lies a less visible layer of inefficiency…
The structural barriers that prevent optimal vendor selection in the first place.
Providers are difficult to compare.
Services are bespoke, pricing is opaque, and capability descriptions are inconsistent.
As a result, decisions default to known providers, not necessarily optimal ones.
The full market is rarely visible.
Regional specialists, emerging CDMOs with available capacity, and academic core facilities with relevant equipment often remain entirely invisible to teams sourcing through traditional channels.
We felt this frustration first-hand. In our time inside biotech and research teams we had no structured way to know who offered what, at what scale, or whether they had relevant capacity.
Or an easy way to showcase our lab’s capabilities to external teams.
We spent more time hunting for providers than evaluating them.
Incumbent providers retain pricing power not because they are always the best option, but because they are the most discoverable one.
Procurement is also relationship-driven.
Personal networks dominate vendor selection across the industry, while reputation and prior experience routinely outweigh rigorous comparative evaluation.
This is understandable in a sector where trust matters, but it means capital is not always deployed to the most capable or cost-effective provider. Just the most familiar one.
For investors, this is not “inefficiency”, but it materially impacts the company's burn rate, timelines, and dilution.
A Structural Shift
This kind of fragmentation is not unique to biotech in Australia.
Manufacturing, logistics, and professional services all faced similar challenges before infrastructure was built around supplier discovery and procurement.
The pattern, when that infrastructure emerges, is consistent.
More visibility brings more providers into competitive view.
Standardisation makes evaluation faster. Centralisation removes duplication. The result is that more of the budget reaches the actual work.
The investor implication is straightforward: when procurement improves, more capital reaches the science.
Faster sourcing accelerates milestones, and better vendor selection reduces execution risk.
Each dollar raised goes further.
Australia is early in this transition but the infrastructure that supports it is still being built.
What This Means for Investors
Most financial models for ASX biotech companies capture the science, the pipeline, the trial timelines, and the probability of approval.
Fewer capture the operational layer sitting underneath it.
So, here are five questions that you can ask the company to evaluate whether it is managing its supplier networks and looking after your capital:
How do you identify new providers? When did you last go to competitive tender?
What criteria do you use to select a service provider, and can you walk through a recent decision?
How long does it typically take from identifying a capability need to having a shortlist of providers ready to quote?
What happens when your preferred provider isn't available or quotes too high?
How much internal time goes into sourcing and managing providers and is that captured in your cost base?
If the company has a strategy for sourcing service providers and making procurement decisions, then it is clearly executing the operational layer efficiently.
Where each raised dollar reaches its intended purpose, and it is spending money (your money) in a way that is capital-efficient to reach the desired outcome.
It doesn’t change the results of a trial.
But it does reduce the dilution over the course of the journey.
If you’re the CEO of a biotech company, take note.
Finding the right CROs, CDMOs, and specialist labs often takes up more of your team’s time than it should.
We built Pipeline Bio to fix that. A centralised platform that makes Australian scientific service providers discoverable, comparable, and engageable in one place.
We’d love to get your perspectives. Visit the website at https://www.pipelinebio.com or reach out to us directly at [email protected].
The Armchair Take
First, thanks so much to James and Nenad.
I know firsthand how frustrating it can be, as an investor, to see cost escalation in research and development over the journey.
These costs are unavoidable (companies need to do ‘stuff’)
BUT if the company acts as a proper steward of capital, it will have strategies in place to ensure that costs are managed and not egregious.
Particularly in the current funding environment for early-stage biotech companies.
Ultimately, the cash is the company’s clock…
If the company doesn’t build its cash balance to build value in the company, then it will inevitably be back hat in hand asking for more at a lower price.
See you all tomorrow,
The Armchair Analyst
